FOR IMMEDIATE RELEASE

Contact: Jonathan Adam Barash Email: [email protected] Phone: 516‑900‑2606 Website: www.oncofirmdiagnostics.com

OncoFirm Diagnostics Corp. Announces Launch and Opens First Funding Round Up to $10 Million

Advancing Early Cancer Detection Through Rapid, Antigen‑Based Screening Technology

Port Washington, New York — April 7 — OncoFirm Diagnostics Corp., an emerging leader in medical diagnostics, today announced its official launch and the opening of its first investment round, offering up to $10 million in funding opportunities for qualified investors. This capital will accelerate regulatory clearance, commercial‑scale manufacturing, clinical validation, and global expansion of the company’s rapid cancer screening platform.

Powered by advanced lateral flow assay (LFA) technology and targeting tumor‑specific Thomsen‑Friedenreich (TF) and Gal‑GalNAc antigens, OncoFirm’s tests deliver non‑invasive, cost‑effective, and highly accurate cancer detection—with results in under 15 minutes at the point of care.

“Our mission is to democratize early cancer detection,” said Jonathan Adam Barash, Founder and CEO of OncoFirm Diagnostics. “By leveraging our antigen‑driven technology, we’re equipping healthcare providers with fast, affordable, and accessible tools to detect cancer earlier—even in settings without traditional laboratory infrastructure.”

Pipeline of Rapid Cancer Screening Tests

OncoFirm’s initial product line includes:

• OncoScreen‑R — Colorectal & pancreatic cancer

• OncoScreen‑B — Breast & ovarian cancer

• OncoScreen‑L — Lung cancer panel

• OncoMultiDx — Multiplex test detecting multiple cancers from a single sample

• OncoScreen‑PSA — Prostate cancer

• OncoScreen‑AFP — Liver cancer

• OncoScreen‑CEA — Gastrointestinal cancers

The company is preparing for CE‑mark pre‑launch in Europe, Latin America, and Asia, with FDA submission underway for U.S. market entry. Funding will also support expansion in R&D, regulatory affairs, and commercial operations.

Investment Highlights

• Target raise: $10 million (Seed + Series A)

• Use of funds: Final product development, CE/FDA regulatory clearance, clinical trials, manufacturing scale‑up, hiring

• Market opportunity: Global cancer diagnostics market projected to exceed $280 billion by 2030

• Strategic focus: Underserved screening markets and decentralized healthcare environments

“We’re operating at the intersection of global need and scientific innovation,” Barash added. “This funding round offers investors a chance to join us at a pivotal moment—not just for OncoFirm, but for the future of early cancer detection.”

About OncoFirm Diagnostics

OncoFirm Diagnostics develops rapid cancer screening tests using proprietary antigen targeting and next‑generation lateral flow technology. Designed for medical institutions and point‑of‑care environments, OncoFirm’s solutions are reshaping early detection and expanding global access to life‑saving diagnostics.

Investment Inquiries

Jonathan Adam Barash Investor Relations, OncoFirm Diagnostics [email protected] | 516‑900‑2606 www.oncofirmdiagnostics.com